https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.031208
4.Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and
outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
China: a single-centered, retrospective, observational study. The Lancet
Respiratory Medicine. 2020 May 1;8(5):475–81.
5.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan, China. The
Lancet. 2020 Feb;395(10223):497–506.
6.Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al.
Complement associated microvascular injury and thrombosis in the
pathogenesis of severe COVID-19 infection: A report of five cases.
Translational Research. 2020 Jun;220:1–13.
7.Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM,
et al. Confirmation of the high cumulative incidence of thrombotic
complications in critically ill ICU patients with COVID-19: An updated
analysis. Thrombosis Research. 2020 Jul;191:148–50.
8.Cheung CY, Poon LLM, Ng IHY, Luk W, Sia S-F, Wu MHS, et al. Cytokine
Responses in Severe Acute Respiratory Syndrome Coronavirus-Infected
Macrophages In Vitro: Possible Relevance to Pathogenesis. Journal of
Virology. 2005 Jun 15;79(12):7819–26.
9.Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of
Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan,
China. Clin Infect Dis. 2020 Jul 28;71(15):762–8.
10.Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R,
Zinkernagel AS, et al. Endothelial cell infection and Endotheliitis in
COVID-19. The Lancet. 2020 May;395(10234):1417–8.
11.Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus
Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and
Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr
1;11(7):995–8.
12.Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C,
Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in
intensive care unit: A report of thromboelastography findings and other
parameters of hemostasis. Journal of Thrombosis and Haemostasis.
2020;18(7):1738–42.
13.Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant
KM, et al. incidence of thrombotic complications in critically ill ICU
patients with COVID-19. Thrombosis Research. 2020 Jul;191:145–7.
14.Jenny NS, Callas PW, Judd SE, McClure LA, Kissela B, Zakai NA, et al.
Inflammatory cytokines, and ischemic stroke risk. Neurology. 2019 May
14;92(20):e2375.
15.Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. JAD.
2020 Jun 30;76(1):3–19.
16.Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic
Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in
Wuhan, China. JAMA Neurol. 2020 Jun 1;77(6):683–90.
17.Han H, Yang L, Liu R, Liu F, Wu K, Li J, et al. Prominent changes in
blood coagulation of patients with SARS-CoV-2 infection. Clinical
Chemistry and Laboratory Medicine (CCLM). 2020 Jun 25;58(7):1116–20.
18.Merkler AE, Parikh NS, Mir S, Gupta A, Kamel H, Lin E, et al. Risk of
Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs.
Patients With Influenza. JAMA Neurology [Internet]. 2020 Jul 2
[cited 2020 Aug7]; doi.org/10.1001/jamaneurol.2020.2730
19.Connors JM, Levy JH. Thromboinflammation and the hypercoagulability
of COVID-19. Journal of Thrombosis and Haemostasis. 2020;18(7):1559–61.
20.Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi
M, et al. Tocilizumab in patients with severe COVID-19: a retrospective
cohort study. The Lancet Rheumatology. 2020 Aug 1;2(8):e474–84.